PREVIOTOX

Helps physicians identify the risk of adverse events to immune checkpoint inhibitors.

PREVIOTOX Testing

While immunotherapy has been a breakthrough in cancer treatment, patients often experience a new type of side effect, referred to as Immune-Related Adverse Events (irAEs). We have found that the germline genetic mutations we study at MiraDx can help predict a patient’s risk of irAEs from immune therapy.

Our first panel, PREVIOTOX, predicts up to a 9-fold increased risk of irAEs from treatment with anti-PD1 or anti-PDL1 therapies.

PREVIOTOX Testing Populations

Patients with any type of cancer who are being considered for anti-PD1 or anti-PDL1 therapy are eligible for testing. This test predicts the risk of developing immune related adverse events in response to anti-PD1 or anti-PDL1 treatment.

If you're interested in PREVIOTOX testing, please contact us.